
国际妇产科学杂志 ›› 2021, Vol. 48 ›› Issue (1): 41-46.doi: 10.12280/gjfckx.20200425
收稿日期:2020-05-19
出版日期:2021-02-15
发布日期:2021-03-01
通讯作者:
王晓慧
E-mail:xiaohuiwang2015@163.com
XIN Yu-qi, TIAN Lei, WANG Xiao-hui△(
)
Received:2020-05-19
Published:2021-02-15
Online:2021-03-01
Contact:
WANG Xiao-hui
E-mail:xiaohuiwang2015@163.com
摘要:
宫颈癌是常见的妇科恶性肿瘤之一,其病因已较明确,主要是人乳头瘤病毒(HPV)的持续感染。近年来,随着预防疫苗问世及筛查工作的普及,宫颈癌早期诊断及早期治疗取得了一些成效,但其发生率及死亡率仍较高,严重威胁女性生命健康。积极探寻宫颈癌早期诊断和治疗方法,可进一步提高宫颈癌患者的预后。长链非编码RNA(lncRNA)是一种无蛋白质编码功能的RNA,参与多种生物学过程。lncRNA在多种恶性肿瘤中异常表达,起到致癌或抑癌的作用。越来越多的研究发现,lncRNA与宫颈癌密切相关,并在宫颈癌的发生、侵袭、转移和耐药性等方面起重要作用。探讨肺腺癌转移相关转录子1(MALAT1)、HOX反义基因间RNA(HOTAIR)、细胞周期激酶抑制因子4基因座中反义非编码RNA(ANRIL)、EBIC、CCHE1等lncRNAs在宫颈癌发生、发展中的作用,概述其在宫颈癌中的分子机制,为宫颈癌的早期诊断和靶向治疗提供新的思路。
辛玉琦, 田蕾, 王晓慧. 长链非编码RNA在宫颈癌发生、发展中作用的研究进展[J]. 国际妇产科学杂志, 2021, 48(1): 41-46.
XIN Yu-qi, TIAN Lei, WANG Xiao-hui. Research Progress on the Role of Long Non-Coding RNA in the Occurrence and Development of Cervical Cancer[J]. Journal of International Obstetrics and Gynecology, 2021, 48(1): 41-46.
| [1] |
Hu Z, Ma D. The precision prevention and therapy of HPV-related cervical cancer: new concepts and clinical implications[J]. Cancer Med, 2018,7(10):5217-5236. doi: 10.1002/cam4.1501.
doi: 10.1002/cam4.1501 pmid: 30589505 |
| [2] |
Nakisige C, Trawin J, Mitchell-Foster S, et al. Integrated cervical cancer screening in Mayuge District Uganda (ASPIRE Mayuge): a pragmatic sequential cluster randomized trial protocol[J]. BMC Public Health, 2020,20(1):142. doi: 10.1186/s12889-020-8216-9.
doi: 10.1186/s12889-020-8216-9 pmid: 32005202 |
| [3] |
Zhang L, Zhao Y, Tu Q, et al. The role of programmed cell death ligand-1/ programmed cell death-1 (PD-L1/PD-1) in HPV-induced cervical cancer and potential for their use in blockade therapy[J]. Curr Med Chem, 2020. doi: 10.2174/0929867327666200128105459.
pmid: 33583367 |
| [4] |
Arredondo-Robles AV, Rodríguez-López KP, Ávila-Avilés RD. RETRACTED ARTICLE: Long non-coding RNAs in cervical cancer[J]. J Appl Genet, 2020,61(3):405. doi: 10.1007/s13353-020-00545-9.
doi: 10.1007/s13353-020-00545-9 pmid: 31981186 |
| [5] |
Bin X, Hongjian Y, Xiping Z, et al. Research progresses in roles of LncRNA and its relationships with breast cancer[J]. Cancer Cell Int, 2018,18:179. doi: 10.1186/s12935-018-0674-0.
doi: 10.1186/s12935-018-0674-0 pmid: 30459529 |
| [6] |
Sanchez Calle A, Kawamura Y, Yamamoto Y, et al. Emerging roles of long non-coding RNA in cancer[J]. Cancer Sci, 2018,109(7):2093-2100. doi: 10.1111/cas.13642.
doi: 10.1111/cas.13642 pmid: 29774630 |
| [7] |
Peng WX, Koirala P, Mo YY. LncRNA-mediated regulation of cell signaling in cancer[J]. Oncogene, 2017,36(41):5661-5667. doi: 10.1038/onc.2017.184.
doi: 10.1038/onc.2017.184 pmid: 28604750 |
| [8] |
Jiang C, Yang Y, Yang Y, et al. Long Noncoding RNA (lncRNA) HOTAIR Affects Tumorigenesis and Metastasis of Non-Small Cell Lung Cancer by Upregulating miR-613[J]. Oncol Res, 2018,26(5):725-734. doi: 10.3727/096504017X15119467381615.
doi: 10.3727/096504017X15119467381615 pmid: 29187267 |
| [9] |
Gupta RA, Shah N, Wang KC, et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis[J]. Nature, 2010,464(7291):1071-1076. doi: 10.1038/nature08975.
doi: 10.1038/nature08975 pmid: 20393566 |
| [10] |
Srivastava AK, Singh PK, Rath SK, et al. Appraisal of diagnostic ability of UCA1 as a biomarker of carcinoma of the urinary bladder[J]. Tumour Biol, 2014,35(11):11435-11442. doi: 10.1007/s13277-014-2474-z.
doi: 10.1007/s13277-014-2474-z pmid: 25123267 |
| [11] | Liu J, Peng WX, Mo YY, et al. MALAT1-mediated tumorigenesis[J]. Front Biosci(Landmark Ed), 2017,22:66-80. |
| [12] |
Prensner JR, Iyer MK, Balbin OA, et al. Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression[J]. Nat Biotechnol, 2011,29(8):742-749. doi: 10.1038/nbt.1914.
doi: 10.1038/nbt.1914 pmid: 21804560 |
| [13] |
Li ZX, Zhu QN, Zhang HB, et al. MALAT1: a potential biomarker in cancer[J]. Cancer Manag Res, 2018,10:6757-6768. doi: 10.2147/CMAR.S169406.
doi: 10.2147/CMAR.S169406 pmid: 30584369 |
| [14] |
Jiang Y, Li Y, Fang S, et al. The role of MALAT1 correlates with HPV in cervical cancer[J]. Oncol Lett, 2014,7(6):2135-2141. doi: 10.3892/ol.2014.1996.
doi: 10.3892/ol.2014.1996 |
| [15] |
Shen F, Zheng H, Zhou L, et al. Overexpression of MALAT1 contributes to cervical cancer progression by acting as a sponge of miR-429[J]. J Cell Physiol, 2019,234(7):11219-11226. doi: 10.1002/jcp.27772.
doi: 10.1002/jcp.27772 pmid: 30515786 |
| [16] |
Zhao F, Fang T, Liu H, et al. Long non-coding RNA MALAT1 promotes cell proliferation, migration and invasion in cervical cancer by targeting miR-625-5p and AKT2[J]. Panminerva Med, 2020. doi: 10.23736/S0031-0808.
doi: 10.23736/S0031-0808.21.04303-2 pmid: 33528152 |
| [17] |
Wang N, Hou MS, Zhan Y, et al. MALAT1 promotes cisplatin resistance in cervical cancer by activating the PI3K/AKT pathway[J]. Eur Rev Med Pharmacol Sci, 2018,22(22):7653-7659. doi: 10.26355/eurrev_201811_16382.
doi: 10.26355/eurrev_201811_16382 pmid: 30536307 |
| [18] |
Tang Q, Hann SS. HOTAIR: An Oncogenic Long Non-Coding RNA in Human Cancer[J]. Cell Physiol Biochem, 2018,47(3):893-913. doi: 10.1159/000490131.
doi: 10.1159/000490131 pmid: 29843138 |
| [19] |
Liu M, Jia J, Wang X, et al. Long non-coding RNA HOTAIR promotes cervical cancer progression through regulating BCL2 via targeting miR-143-3p[J]. Cancer Biol Ther, 2018,19(5):391-399. doi: 10.1080/15384047.2018.1423921.
doi: 10.1080/15384047.2018.1423921 pmid: 29336659 |
| [20] |
Zhang Y, Cheng X, Liang H, et al. Long non-coding RNA HOTAIR and STAT3 synergistically regulate the cervical cancer cell migration and invasion[J]. Chem Biol Interact, 2018,286:106-110. doi: 10.1016/j.cbi.2018.03.010.
pmid: 29572071 |
| [21] |
Li Q, Feng Y, Chao X, et al. HOTAIR contributes to cell proliferation and metastasis of cervical cancer via targetting miR-23b/MAPK1 axis[J]. Biosci Rep, 2018,38(1). doi: 10.1042/BSR20171563.
doi: 10.1042/BSR20171551 pmid: 29273678 |
| [22] |
Guo X, Xiao H, Guo S, et al. Long noncoding RNA HOTAIR knockdown inhibits autophagy and epithelial-mesenchymal transition through the Wnt signaling pathway in radioresistant human cervical cancer HeLa cells[J]. J Cell Physiol, 2019,234(4):3478-3489. doi: 10.1002/jcp.26828.
doi: 10.1002/jcp.26828 pmid: 30367473 |
| [23] | Kong Y, Hsieh CH, Alonso LC. ANRIL: A lncRNA at the CDKN2A/B Locus With Roles in Cancer and Metabolic Disease[J]. Front Endocrinol(Lausanne), 2018,9:405. doi: 10.3389/fendo.2018.00405. |
| [24] |
Zhang D, Sun G, Zhang H, et al. Long non-coding RNA ANRIL indicates a poor prognosis of cervical cancer and promotes carcinogenesis via PI3K/Akt pathways[J]. Biomed Pharmacother, 2017,85:511-516. doi: 10.1016/j.biopha.2016.11.058.
doi: 10.1016/j.biopha.2016.11.058 pmid: 27899255 |
| [25] |
Zhang JJ, Wang DD, Du CX, et al. Long Noncoding RNA ANRIL Promotes Cervical Cancer Development by Acting as a Sponge of miR-186[J]. Oncol Res, 2018,26(3):345-352. doi: 10.3727/096504017X14953948675449.
doi: 10.3727/096504017X14953948675449 pmid: 28550682 |
| [26] |
Zhang WY, Liu YJ, He Y, et al. Down-regulation of long non-coding RNA ANRIL inhibits the proliferation, migration and invasion of cervical cancer cells[J]. Cancer Biomark, 2018,23(2):243-253. doi: 10.3233/CBM-181467.
doi: 10.3233/CBM-181467 pmid: 30198868 |
| [27] |
Gutschner T, Diederichs S. The hallmarks of cancer: a long non-coding RNA point of view[J]. RNA Biol, 2012,9(6):703-719. doi: 10.4161/rna.20481.
doi: 10.4161/rna.20481 |
| [28] |
Naemura M, Murasaki C, Inoue Y, et al. Long Noncoding RNA ANRIL Regulates Proliferation of Non-small Cell Lung Cancer and Cervical Cancer Cells[J]. Anticancer Res, 2015,35(10):5377-5382.
pmid: 26408699 |
| [29] |
Sun NX, Ye C, Zhao Q, et al. Long noncoding RNA-EBIC promotes tumor cell invasion by binding to EZH2 and repressing E-cadherin in cervical cancer[J]. PLoS One, 2014,9(7):e100340. doi: 10.1371/journal.pone.0100340.
doi: 10.1371/journal.pone.0100340 pmid: 25007342 |
| [30] |
Wang C, Liu X, Chen Z, et al. Polycomb group protein EZH2-mediated E-cadherin repression promotes metastasis of oral tongue squamous cell carcinoma[J]. Mol Carcinog, 2013,52(3):229-236. doi: 10.1002/mc.21848.
doi: 10.1002/mc.21848 pmid: 22161744 |
| [31] |
Yang M, Zhai X, Xia B, et al. Long noncoding RNA CCHE1 promotes cervical cancer cell proliferation via upregulating PCNA[J]. Tumour Biol, 2015,36(10):7615-7622. doi: 10.1007/s13277-015-3465-4.
doi: 10.1007/s13277-015-3465-4 pmid: 25921283 |
| [32] |
Chen Y, Wang CX, Sun XX, et al. Long non-coding RNA CCHE1 overexpression predicts a poor prognosis for cervical cancer[J]. Eur Rev Med Pharmacol Sci, 2017,21(3):479-483.
pmid: 28239824 |
| [33] |
Qu X, Li Y, Wang L, et al. LncRNA SNHG8 accelerates proliferation and inhibits apoptosis in HPV-induced cervical cancer through recruiting EZH2 to epigenetically silence RECK expression[J]. J Cell Biochem, 2020,121(10):4120-4129. doi: 10.1002/jcb.29646.
doi: 10.1002/jcb.29646 pmid: 31961005 |
| [34] |
Tian W, Lei N, Guo R, et al. Long non-coding RNA DANCR promotes cervical cancer growth via activation of the Wnt/β-catenin signaling pathway[J]. Cancer Cell Int, 2020,20:61. doi: 10.1186/s12935-020-1139-9.
doi: 10.1186/s12935-020-1139-9 pmid: 32123519 |
| [35] |
Yu X, Zheng H, Chan MT, et al. HULC: an oncogenic long non-coding RNA in human cancer[J]. J Cell Mol Med, 2017,21(2):410-417. doi: 10.1111/jcmm.12956.
doi: 10.1111/jcmm.12956 pmid: 27781386 |
| [36] |
Wang YF, Zhang S, Li XQ, et al. Expression of lncRNA HULC in cervical cancer and its correlation with tumor progression and patient survival[J]. Eur Rev Med Pharmacol Sci, 2016,20(19):3987-3991.
pmid: 27775802 |
| [37] |
Lu W, Wan X, Tao L, et al. Long Non-Coding RNA HULC Promotes Cervical Cancer Cell Proliferation, Migration and Invasion via miR-218/TPD52 Axis[J]. Onco Targets Ther, 2020,13:1109-1118. doi: 10.2147/OTT.S232914.
doi: 10.2147/OTT.S232914 pmid: 32103980 |
| [38] |
Poliseno L, Haimovic A, Christos PJ, et al. Deletion of PTENP1 pseudogene in human melanoma[J]. J Invest Dermatol, 2011,131(12):2497-2500. doi: 10.1038/jid.2011.232.
doi: 10.1038/jid.2011.232 pmid: 21833010 |
| [39] |
Gao X, Qin T, Mao J, et al. PTENP1/miR-20a/PTEN axis contributes to breast cancer progression by regulating PTEN via PI3K/AKT pathway[J]. J Exp Clin Cancer Res, 2019,38(1):256. doi: 10.1186/s13046-019-1260-6.
doi: 10.1186/s13046-019-1260-6 pmid: 31196157 |
| [40] |
Fan Y, Sheng W, Meng Y, et al. LncRNA PTENP1 inhibits cervical cancer progression by suppressing miR-106b[J]. Artif Cells Nanomed Biotechnol, 2020,48(1):393-407. doi: 10.1080/21691401.2019.1709852.
doi: 10.1080/21691401.2019.1709852 pmid: 31913710 |
| [1] | 郑晓琳, 魏芳. LPCAT1在妇科恶性肿瘤中的研究进展[J]. 国际妇产科学杂志, 2026, 53(3): 273-277. |
| [2] | 何倩楠, 黄子杰, 王一帆, 安雨声, 冯淑娴. PAX1/JAM3双基因联合甲基化检测在宫颈病变管理中的研究进展[J]. 国际妇产科学杂志, 2026, 53(3): 278-284. |
| [3] | 相骁莹, 孙雅歌, 张云凤, 贾涵, 王悦. p53突变型子宫内膜癌免疫微环境特征及免疫治疗进展[J]. 国际妇产科学杂志, 2026, 53(3): 285-291. |
| [4] | 王薇, 戴柏, 沙日娜, 托娅. 驱动蛋白家族成员18B在子宫内膜癌中的作用机制与分子分型关联分析[J]. 国际妇产科学杂志, 2026, 53(3): 292-297. |
| [5] | 武化拓, 黄春林, 马焱, 葛挺, 李莉. 卵巢癌免疫微环境研究进展[J]. 国际妇产科学杂志, 2026, 53(3): 297-301. |
| [6] | 郑乐, 张新, 贾海清. 胎盘部位滋养细胞肿瘤肺转移患者化疗联合胸腔镜手术一例[J]. 国际妇产科学杂志, 2026, 53(3): 302-305. |
| [7] | 尹第霜, 李囡, 郭红霞. 高级别子宫内膜间质肉瘤与子宫内膜样腺癌碰撞瘤一例[J]. 国际妇产科学杂志, 2026, 53(3): 311-317. |
| [8] | 刘尔愉, 任青于, 高翔. 复发性宫颈癌伴膀胱-小肠瘘一例[J]. 国际妇产科学杂志, 2026, 53(3): 322-328. |
| [9] | 杨燕, 闫锴, 周登莲, 邓鑫. 外泌体在子宫内膜纤维化中的作用机制与潜在诊疗应用[J]. 国际妇产科学杂志, 2026, 53(3): 335-340. |
| [10] | 刘栋, 郭洁, 宋殿荣. 阴道微生物组及其代谢产物对HPV感染及宫颈病变的影响及作用机制[J]. 国际妇产科学杂志, 2026, 53(3): 341-346. |
| [11] | 其格乐, 乔峤. 冷诱导RNA结合蛋白诱导阴道黏膜上皮损伤导致下生殖道感染的研究进展[J]. 国际妇产科学杂志, 2026, 53(2): 137-142. |
| [12] | 刘欣, 许思娟. 代谢组学评估反复着床失败妇女子宫内膜容受性的研究进展[J]. 国际妇产科学杂志, 2026, 53(2): 165-169. |
| [13] | 徐梦婷, 鲁娣, 宋殿荣. 卵巢癌肿瘤微环境相关研究进展[J]. 国际妇产科学杂志, 2026, 53(2): 188-193. |
| [14] | 韦林媛, 潘忠勉, 李力. 中心体蛋白2通过调控DNA损伤修复促进上皮性卵巢癌铂类耐药的研究进展与展望[J]. 国际妇产科学杂志, 2026, 53(2): 194-199. |
| [15] | 王冰燕, 李凤虎. 生殖道微生物组在宫颈癌中的研究进展[J]. 国际妇产科学杂志, 2026, 53(2): 200-205. |
| 阅读次数 | ||||||
|
全文 |
|
|||||
|
摘要 |
|
|||||